Results Of Patient Rated Asthma Control Test In Comparison To Diary Card Data

Asthma Control Assessment Via ACT and DRC in Asthmatics Treated With Seretide (50/250) Over 12 Weeks

The majority of asthma patients are not well controlled, despite the availability of asthma medication that could effectively treat the disease. In this study uncontrolled patients who are steroid-naive or on low dose inhaled corticosteroids will be treated with Seretide (salmeterol/fluticasone combination, SFC) 50/250 µg twice daily. The asthma control test (ACT) will be used to detect differences in the level of asthma control during treatment. The study aims to show a correlation between improvements of ACT und the level of asthma control which will be reached by the patients.

The aim of the study is to show that most of symptomatic asthma patients can reach 'well controlled asthma' with SFC. We get information about ACT in daily practice and physicians are trained to use the asthma control test as a screening tool and for follow up of asthma management. Correlations are expected between the improvements in ACT, Quality of Life and asthma control according to the Gaining Optimal Asthma controL (GOAL) criteria.

Study Overview

• Status: Completed
• Conditions: Asthma
• Intervention / Treatment: Drug: Salmeterol/Fluticasone 50/250 mcg; Drug: Salbutamol 100 mcg; Device: DISKUS™ powder inhalers

• Study Type: Interventional
• Enrollment (Actual): 221
• Phase: Phase 4

Contacts and Locations

Study Locations

• Germany
  • Berlin, Germany, 10367
    • GSK Investigational Site
  • Berlin, Germany, 10717
    • GSK Investigational Site
  • Berlin, Germany, 13187
    • GSK Investigational Site
  • Berlin, Germany, 13597
    • GSK Investigational Site
  • Berlin, Germany, 10965
    • GSK Investigational Site
  • Berlin, Germany, 12687
    • GSK Investigational Site
  • Berlin, Germany, 12165
    • GSK Investigational Site
  • Hamburg, Germany, 22767
    • GSK Investigational Site
  • Bayern
    • Erlangen, Bayern, Germany, 91052
      • GSK Investigational Site
    • Kaufbeuren, Bayern, Germany, 87600
      • GSK Investigational Site
    • Landsberg, Bayern, Germany, 86899
      • GSK Investigational Site
    • Muenchen, Bayern, Germany, 81677
      • GSK Investigational Site
    • Muenchen, Bayern, Germany, 80335
      • GSK Investigational Site
    • Rednitzhembach, Bayern, Germany, 91126
      • GSK Investigational Site
    • Uttenreuth, Bayern, Germany, 91080
      • GSK Investigational Site
    • Wuerzburg, Bayern, Germany, 97070
      • GSK Investigational Site
  • Brandenburg
    • Cottbus, Brandenburg, Germany, 03050
      • GSK Investigational Site
  • Hamburg
    • Wedel, Hamburg, Germany, 22880
      • GSK Investigational Site
  • Hessen
    • Bad Arolsen, Hessen, Germany, 34454
      • GSK Investigational Site
    • Eschwege, Hessen, Germany, 37269
      • GSK Investigational Site
    • Kassel, Hessen, Germany, 34121
      • GSK Investigational Site
    • Kassel, Hessen, Germany, 34117
      • GSK Investigational Site
    • Marburg, Hessen, Germany, 35037
      • GSK Investigational Site
  • Niedersachsen
    • Braunschweig, Niedersachsen, Germany, 38100
      • GSK Investigational Site
    • Buchholz, Niedersachsen, Germany, 21244
      • GSK Investigational Site
    • Hannover, Niedersachsen, Germany, 30159
      • GSK Investigational Site
    • Hannover, Niedersachsen, Germany, 30167
      • GSK Investigational Site
  • Sachsen
    • Chemnitz, Sachsen, Germany, 09126
      • GSK Investigational Site
    • Dresden, Sachsen, Germany, 01099
      • GSK Investigational Site
  • Schleswig-Holstein
    • Geesthacht, Schleswig-Holstein, Germany, 21502
      • GSK Investigational Site
  • Thueringen
    • Greiz, Thueringen, Germany, 07973
      • GSK Investigational Site
    • Sonneberg, Thueringen, Germany, 96515
      • GSK Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion criteria:

• Diagnosis of asthma
• Reversibility >12% after inhalation of 200 µg Salbutamol
• willingness and ability to complete daily record card on daily basis and to measure morning PEF on daily basis
• 80% compliance in diary card completion asthma control status: Uncontrolled based on the GOAL criteria

Exclusion criteria:

• Change of asthma medication during the last 4 weeks
• Asthma exacerbation characterized by use of oral corticoids during the last 3 months Pretreatment with inhaled corticosteroids more than 500 mcg Beclometasondipropionat or equivalent per day or other controller therapy during the last 3 months
• upper or lower respiratory tract infection during the RUN-IN period moderate or severe asthma exacerbation during the RUN-IN period
• Non compliance with use of Discus, PEF-meter and incomplete diary card data

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NON_RANDOMIZED
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

EXPERIMENTAL: SFC 50/250 mcg; Participants received the combination product, fluticasone 250 microgram (mcg) plus salmeterol 50 mcg (SFC 50/250 mcg) for 12 weeks. Study treatment was received using DISKUS™ powder inhalers, one dose in morning and evening. Study medication was dispensed at visits 3, 4, and 5 for 30 days each. The participants were provided with salbutamol rescue medication if they developed acute asthmatic symptoms. This medication was provided in metered dose inhalers containing at least 200 puffs of 100 mcg salbutamol. Use of rescue medications was recorded in the participant's asthma diaries. Stable dosages of other concomitant medications were allowed if they had no impact on the outcome criteria.

Drug: Salmeterol/Fluticasone 50/250 mcg; Participant received salmeterol/fluticasone combination 50/250 mcg using DISKUS™ powder inhalers.; Drug: Salbutamol 100 mcg; This medication was provided in metered dose inhalers containing at least 200 puffs of 100 mcg salbutamol.; Device: DISKUS™ powder inhalers; Participant received salmeterol and fluticasone using DISKUS™ powder inhalers.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Well Controlled Participants as Per Gaining Optimal Asthma Control (GOAL) Criteria After 12 Week Compared to Percentage of Participants With Asthma Control Test (ACT) Score of 20-25 for Week 9 to Week 12	A week with well controlled asthma, when two or more of the criteria were fulfilled (diary entries): At most 2 days per week with 24-hour symptom score >1 (Range: 0= None to 5= severe), rescue salbutamol use on <= 2 days and at most 4 occasions per week, and a morning peak flow >= 80% of the predicted value on each day per week. All of the criteria which includes no night-time awakenings due to asthma (diary entry), no emergency visits (diary entry), no exacerbations and no treatment-related adverse events leading to treatment change are fulfilled. The total ACT score is based on a range of 5 to 25. Higher score indicates better asthma control. A score of 19 or less may be a sign that asthma symptoms are not under control.	Week 9 to Week 12

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Percentage of Participants With ACT Score of 20-25 at Week 12	The total ACT score is based on a range of 5 to 25. Higher score indicates better asthma control. A score of 19 or less may be a sign that asthma symptoms are not under control. In order to derive the total ACT score, all 5 questions needed to be answered. Change from baseline value was calculated by subtracting baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.	Baseline (Visit 3) and Week 12
Change From Baseline in Mean ACT Score at Visit 6	The total ACT score is based on a range of 5 to 25. Higher score indicates better asthma control. A score of 19 or less may be a sign that asthma symptoms not under control. In order to derive the total ACT score, all 5 questions had to be answered. Change from baseline value was calculated by subtracting baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.	Baseline (Viait 3) and Week 12
Number of Participants With Well Controlled and Totally Controlled Asthma at Week 12	Well controlled or totally controlled asthma assessments were done according to the GOAL criteria. A week with well controlled asthma, when two or more of the criteria were fulfilled (diary entries): At most 2 days per week with 24-hour symptom score >1(Range: 0= None to 5= severe), rescue salbutamol use on <= 2 days and at most 4 occasions per week, and morning peak flow >= 80% of the predicted value on each day per week. All of the criteria which included no night-time awakenings due to asthma (diary entry),no emergency visits (diary entry), no exacerbations and no treatment-related adverse events leading to treatment change were fulfilled. The total ACT score was based on a range of 5 to 25. Higher score indicates better asthma control. A score of 19 or less may be a sign that asthma symptoms are not under control. Change from baseline value was calculated by subtracting baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.	Week 12
Change From Baseline in Quality of Life Using the Asthma Quality of Life Questionnaire (AQLQ)	For the level of asthma control, baseline values were derived taking the last 8 weeks during the pre-treatment period prior to Visit 3 into consideration. Regarding derived variables based on the asthma diary, data from the last week prior to Visit 3 was taken. Visit 3, regarded as baseline. AQLQ has 32 questions regarding activities, emotions, symptoms, and environmental triggers. Each item values range from 1 (maximum impairment) to 7 (no impairment). A positive change from baseline score indicates improvement.	Baseline (Visit 3) up to Week 12
Correlation of Change in AQLQ Score and Change in ACT Score	Correlation between change in the AQLQ and ACT score was tabulated using the Pearson coefficient of correlation (linear correlation). The AQLQ contained 32 items in 4 domains: activity limitation, symptoms, emotional function and environmental stimuli. Scores for the domains as well as the overall score were scaled within a range of 1 (worst) to 7 (best).	Week 12
Change From Baseline in Forced Expiratory Volume (FEV1) to Week 12	FEV1, an amount of air exhaled by a person during a forced breath in one second. FEV1 assessed at Visit 1 and at Visits 3, 4, 5, 6. Baseline was the measurement at Visit 3. Change from baseline value was calculated by subtracting baseline value from week 12 value.	Baseline (Visit 3) up to Week 12
Change From Baseline in Mean Morning Percent Predicted Peak Expiratory Flow (PEF) at Week 12	PEF, a person's maximum speed of expiration, as measured with a peak flow meter, a small, hand-held device used to monitor a person's ability to breathe out air. The mean morning PEF evaluated by means of the data documented in the asthma diaries. Change from baseline value was calculated by subtracting baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.	Baseline (Visit 3) and Week 12
Change From Baseline in Mean 24-hour Symptom Score at Week 12	The various symptoms like wheezing, shortness of breath, coughing and chest tightness were assessed by the participants every morning using a symptom score scale which ranged from 0 (no symptoms during the past 24 hours) to 5 (symptoms so severe that participant could not go to work or carry out other normal daily activities). Change from baseline value was calculated by subtracting baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.	Baseline (Visit 3) and Week 12
Change From Baseline in Number of Additional Usage of Salbutamol at Week 12	Salbutamol was given as a rescue medicine, used on <= 2 days and at most 4 occasions per week. Change from baseline value was calculated by subtracting the baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.	Baseline (Visit 3) and week 12
Percent Change From Baseline in Number of Nights With no Nocturnal Awakening at Week 12	Number of nights with no night time awakening were recorded at Week 12. Baseline was the last corresponding time period immediately prior to Visit 3.	Baseline (Visit 3) and week 12
Number of Participants With Emergency Visits Due to Asthma	Frequencies of emergency visits per participant were recorded during treatment period. Only the participants at risk were considered when calculating the incidence rates.	Up to week 12
Number of Participants With Adverse Events (AE) Leading to a Change in Asthma Treatment	AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which did not necessarily have a causal relationship with the treatment. Number of participants with AE who lead to change in asthma treatment were reported.	Up to Week 12
Assessment of Tolerability by Number of Participants With at Least One Treatment Emergent Serious and, Non-serious AE	An AE is any untoward medical occurrence in a participant or clinical AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which did not necessarily have a causal relationship with the treatment. Number of participants with at least one treatment emergent serious and, non-serious AE were reported.	Up to Week 12
Assessment of Tolerability by Change From Baseline of Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	SBP and DBP were recorded over time (Visit 1, 3, 4, 5, and 6). Baseline was the measurement at Visit 3. Change from baseline value was calculated by subtracting baseline value from week 12 value.	Baseline (Visit 3) up to Week 12
Assessment of Tolerability by Change From Baseline of Pulse Rate	Pulse rate was recorded over time (Visit 1, 3, 4, 5, and 6). Baseline was the measurement at Visit 3. Change from baseline value was calculated by subtracting baseline value from week 12 value.	Baseline (Visit 3) up to Week 12
Number of Participants With Occurrence of (Near-) Incidents Associated With Peak Flow Measurements	Frequencies of participants with at least one (near-) incident associated with peak flow measurements were recorded. analysis was done on safety population.	Up to Week 12

Collaborators and Investigators

• Sponsor: GlaxoSmithKline

Study record dates

Study Major Dates

• Study Start (ACTUAL): May 17, 2006
• Primary Completion (ACTUAL): September 1, 2007
• Study Completion (ACTUAL): September 14, 2007

Study Registration Dates

• First Submitted: August 10, 2006
• First Submitted That Met QC Criteria: August 10, 2006
• First Posted (ESTIMATE): August 15, 2006

Study Record Updates

• Last Update Posted (ACTUAL): March 9, 2018
• Last Update Submitted That Met QC Criteria: March 6, 2018
• Last Verified: March 1, 2018

More Information

Terms related to this study

• Keywords: Asthma; SERETIDE; Asthma Control Test
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Immune System Diseases; Lung Diseases; Hypersensitivity, Immediate; Bronchial Diseases; Lung Diseases, Obstructive; Respiratory Hypersensitivity; Hypersensitivity; Asthma; Physiological Effects of Drugs; Adrenergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Autonomic Agents; Peripheral Nervous System Agents; Anti-Inflammatory Agents; Adrenergic Agonists; Dermatologic Agents; Bronchodilator Agents; Anti-Asthmatic Agents; Respiratory System Agents; Reproductive Control Agents; Anti-Allergic Agents; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Tocolytic Agents; Fluticasone; Albuterol; Salmeterol Xinafoate
• Other Study ID Numbers: SAM 106538